Julian Harrison, an analyst from BTIG, maintained the Buy rating on Abivax SA Sponsored ADR. The associated price target was raised to $112.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Julian Harrison has given his Buy rating due to a combination of factors that highlight the promising outlook for Abivax SA. The company’s ABTECT trials have shown impressive results, particularly with the 50mg dose achieving significant clinical remission rates in ulcerative colitis, which surpassed expectations. This success is further supported by a strong safety profile, comparable to existing treatments like Entyvio, and the potential for broad commercial adoption due to its oral administration and novel mechanism of action.
Moreover, Abivax’s financial position is robust, with sufficient cash reserves to fund operations into late 2027, following a successful public offering. The company’s strategic plans include submitting regulatory applications in the latter half of 2026, contingent on forthcoming maintenance data. These elements, combined with the ongoing development of obefazimod for Crohn’s disease and other indications, underpin the optimistic Buy recommendation.
In another report released on September 1, LifeSci Capital also maintained a Buy rating on the stock with a $116.00 price target.